TB Archives – Page 5 of 49 – Treatment Action Group

TAG Reaction to the Price of GeneXpert Tests

September 19, 2023
Dorrit Walsh

Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing major gaps in TB diagnosis.

Far Off Track: Funding for TB Research, 2018 – 2022

September 19, 2023
Dorrit Walsh

United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to…

TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023

September 12, 2023
Dorrit Walsh

Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV, TB, and HCV.

Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%

August 16, 2023
Dorrit Walsh

In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.

Letter to Dr. Jeanne Marazzo, New Director NIAID

August 10, 2023
Dorrit Walsh

We're excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).

Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

August 1, 2023
Dorrit Walsh

TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.

2023 Pipeline Report

July 20, 2023
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands

July 13, 2023
Dorrit Walsh

After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...

Open Letter: Urgent Action Necessary for Equitable Access to Bedaquiline in All Countries with High Burdens of TB, MDR-TB, and TB/HIV

July 11, 2023
Dorrit Walsh

TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company...

An Activist’s Protocol Review Toolkit

July 11, 2023
Dorrit Walsh

An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.